They do. And reps from every major Pharma company were at the NYAS presentation. You best believe they are following this with bated breath. However, BioTech *is* a business, and if they can buy the company for $2B instead of $40B that is certainly to their advantage. It's in their best interest for the stock price to be low.
Market Data 
Markets 
AI
